Acute Lymphoblastic Leukemia News and Research RSS Feed - Acute Lymphoblastic Leukemia News and Research

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Leukemia cells are abnormal cells that cannot do what normal blood cells do. The abnormal cells are immature white blood cells that cannot help the body fight infections. For this reason, children with ALL often get infections and have fevers.

ALL is also called acute lymphocytic leukemia. It is the most common leukemia in children.
Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA. [More]
Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. [More]
New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

New NCCN Guidelines for treating Acute Lymphoblastic Leukemia

According to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Acute Lymphoblastic Leukemia (ALL), the treatment approach to ALL is one of the most complex and intensive programs in cancer therapy. [More]
MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants this week from the Cancer Prevention and Research Institute of Texas. Approximately half of the funds awarded for Individual Investigator Research Awards went to MD Anderson faculty as well as 40 percent of total IIRA awards that include those for children's and adolescent cancer and early detection and prevention. [More]
Study results pave way for new clinical trial for glioblastoma patients

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research. [More]
Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Adult survivors of childhood cancer at risk for pituitary hormone deficiencies

Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. [More]
Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia. [More]
Drug similar to Gleevec may help tame some brain cancers

Drug similar to Gleevec may help tame some brain cancers

The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth. [More]
Children's Hospital of Philadelphia invited to Obama's announcement of Precision Medicine Initiative

Children's Hospital of Philadelphia invited to Obama's announcement of Precision Medicine Initiative

At the invitation of the White House, The Children's Hospital of Philadelphia (CHOP) sent two special guests to President Barack Obama's announcement today of the Precision Medicine Initiative: Dr. Steven M. Altschuler, CHOP's chief executive officer, and 9-year-old patient Emily Whitehead, now cancer-free thanks to a personalized treatment called T cell therapy, developed at CHOP. [More]
Study identifies genetic basis of drug toxicity in leukemia patients of East Asian ancestry

Study identifies genetic basis of drug toxicity in leukemia patients of East Asian ancestry

January 26, 2015) About 10 percent of young leukemia patients of East Asian ancestry inherit a gene variation that is associated with reduced tolerance of a drug that is indispensable for curing acute lymphoblastic leukemia (ALL), the most common childhood cancer. [More]
CHLA researchers develop new protein-based therapy against drug-resistant leukemia cells

CHLA researchers develop new protein-based therapy against drug-resistant leukemia cells

Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells. [More]
Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell granted FDA and EMA orphan drug designation for NiCord

Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that orphan drug designation has been granted by The US Department of Health and Human Services, The FDA Office of Orphan Products Development (OOPD) for the investigational medicinal product NiCord for the treatment of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and myelodysplastic syndrome (MDS). [More]
FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

FDA approves intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi)

Jazz Pharmaceuticals plc today announced that the U.S. Food and Drug Administration approved the intravenous administration of Erwinaze (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. [More]
Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Genetic variations may contribute to treatment-related cognitive problems in children with ALL

Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to a study led by researchers from Boston Children's Hospital, The Children's Hospital at Montefiore, and Dana-Farber/Boston Children's Cancer and Blood Disorders Center. [More]
Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing Phase II clinical study with its lead product ATIR. [More]
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition. [More]

Adolescent and young adult patients with ALL fare better with high-intensity pediatric protocols

Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients--aged 16 to 39 with acute lymphoblastic leukemia (ALL)--tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens. [More]
Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Innovative cell therapy shows highly promising results in pediatric patients with ALL

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years. [More]
MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). [More]